Half Yearly Report
Half Yearly Report
July 30, 2015 – Shire plc (the “Group”) (LSE: SHP, NASDAQ: SHPG), in accordance with the Financial Conduct Authority's Disclosure Rules and Transparency Rules, is publishing today its Half Yearly Report for the six months ended June 30, 2015.
It should be noted that on July 23, 2015 the Group previously announced its results in respect of the same period.
For further information please contact:
|
Investor Relations |
|
|
|
Sarah Elton-Farr |
+44 1256 894157 | |
|
Media |
|
|
|
Michele Galen |
+1 781 482 1867 | |
|
Brooke Clarke |
+44 1256 894 829 |
Download the PDF for the full release
NOTES TO EDITORS
Shire enables people with life-altering conditions to lead better lives.
Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.
We focus on providing treatments in Rare Diseases, Neuroscience, Gastrointestinal and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmics.